---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-169686"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2022-06-08T23:59:59+00:00"
generated_at: "2026-06-25T03:33:49.535813+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma reports PC14586 Phase 1 data: 32% ORR at high doses, responses in 6 tumor types

## Summary
- Overall response rate (ORR) 32% (8/25) in patients receiving daily dose ≥1150 mg; 24% (8/33) across all doses.
- Partial responses observed in breast, endometrial, prostate, pancreatic, ovarian, and small cell lung cancers.
- Maximum tolerated dose reached at 1500 mg twice daily; common AEs included nausea, vomiting, AST/ALT increases.
- Phase 2 portion of PYNNACLE study expected to start early 2023; data provide proof of concept for p53 reactivation.
- Data presented at ASCO 2022 by MD Anderson investigator; first-in-class small molecule targeting p53 Y220C mutation.

## SEC filing metadata
- accession: 0001193125-22-169686
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2022-06-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000119312522169686/0001193125-22-169686-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000119312522169686/d274688d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-169686
- JSON: https://secwatch.observer/filing/0001193125-22-169686.json
- Plain text: https://secwatch.observer/filing/0001193125-22-169686.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.